Contributors: Direction des maladies infectieuses - Infectious Diseases Division Saint-Maurice; Santé publique France - French National Public Health Agency Saint-Maurice, France; Direction des régions Saint-Maurice (DiRe); Cellule Régionale Ile-de-France Paris; Santé publique France - French National Public Health Agency Saint-Maurice, France -Santé publique France - French National Public Health Agency Saint-Maurice, France; Agence Régionale de Santé Ile-de-France Paris (ARS IDF); Agence Régionale de Santé Nouvelle-Aquitaine Bordeaux (ARS NA); Cellule Régionale Nouvelle-Aquitaine Bordeaux; Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae Paris (CNR - laboratoire coordonnateur); Institut Pasteur Paris (IP); Services de Maladies Infectieuses et Tropicales CHU Bichat; AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Bordeaux GeoSentinel Site Bordeaux; Service des maladies infectieuses et tropicales Bordeaux; CHU Bordeaux-CHU Bordeaux; Laboratoire de Biotechnologie et Microbiologie Appliquée (LBMA); Université Bordeaux Segalen - Bordeaux 2-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord; Centre opérationnel de réception et de régulation des urgences sanitaires et sociales Paris; Direction Générale de la Santé Paris (DGS); Ministère des Solidarités et de la Santé Paris, France -Ministère des Solidarités et de la Santé Paris, France; Direction alerte et crise Santé publique France, Saint-Maurice; Investigation Team : Laurent Filleul, Stéphanie Vandentorren, Guillaume Spaccaferri, Hélène Prouvost, Mélanie Albert, Marion Barbet, Angela Brisebarre, Flora Donati, Sylvie van der Werf, Alexis Ardoin, Marion Dreyer, Karim Tararbit, Matthieu Amodeo, Elodie Couaillier, Pascal Fabre, Daniel Habold, Didier Che, Gisèle Bendjelloul, Marine Billaudelle Lallemant, Valentine Charachon, Laurène Deconinck, Diane Descamps, Sandrine Gérard, Nadirha Houhou, Quentin Le Hingrat, Isabelle Lolom, Jean-Christophe Lucet, Annabelle Pourbaix, Simon Valayer, Yazdan Yazdanpanah, Alexandre Boyer, Benjamin Clouzeau, Xavier Combes, Arnaud Desclaux, Jean-Michel Dindart, Alexandre Duvignaud, Isabelle Garrigue, Didier Gruson, Marie-Edith Lafon, Pauline Perreau, Thierry Pistone, Maxime Poteau, Eric Tentillier, Pauline Mathieu
نبذة مختصرة : International audience ; A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) causing a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, was identified on 7 January 2020. The epidemic quickly disseminated from Wuhan and as at 12 February 2020, 45,179 cases have been confirmed in 25 countries, including 1,116 deaths. Strengthened surveillance was implemented in France on 10 January 2020 in order to identify imported cases early and prevent secondary transmission. Three categories of risk exposure and follow-up procedure were defined for contacts. Three cases of COVID-19 were confirmed on 24 January, the first cases in Europe. Contact tracing was immediately initiated. Five contacts were evaluated as at low risk of exposure and 18 at moderate/high risk. As at 12 February 2020, two cases have been discharged and the third one remains symptomatic with a persistent cough, and no secondary transmission has been identified. Effective collaboration between all parties involved in the surveillance and response to emerging threats is required to detect imported cases early and to implement adequate control measures.
Processing Request
No Comments.